NCT06668974

Brief Summary

This study investigates the causal relationship between allergic rhinitis and asthma using a bidirectional two-sample Mendelian randomization approach. Genetic data were derived from UK Biobank for allergic rhinitis and from Finnish biobank for asthma. This analysis aims to clarify the potential causal link between these two conditions.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
239,607

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2024

Completed
14 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 15, 2024

Completed
13 days until next milestone

Study Completion

Last participant's last visit for all outcomes

October 28, 2024

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

October 30, 2024

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 1, 2024

Completed
Last Updated

November 1, 2024

Status Verified

October 1, 2024

Enrollment Period

14 days

First QC Date

October 30, 2024

Last Update Submit

October 31, 2024

Conditions

Keywords

Mendelian RandomizationGenetic AssociationBidirectional CausalityGenome-Wide Association Study (GWAS)Respiratory Diseases

Outcome Measures

Primary Outcomes (2)

  • Causal Effect of Allergic Rhinitis on Asthma Risk

    Estimate the causal effect of allergic rhinitis on asthma risk using bidirectional Mendelian randomization. This measure includes odds ratios (OR) derived from inverse-variance weighting (IVW), Mendelian randomization-Egger (MR-Egger), and weighted median methods.

    Oct 24 2024

  • Causal Effect of Asthma on Allergic Rhinitis Risk

    Estimate the causal effect of asthma on allergic rhinitis risk using bidirectional Mendelian randomization. This measure includes odds ratios (OR) derived from inverse-variance weighting (IVW), Mendelian randomization-Egger (MR-Egger), and weighted median methods.

    Oct 24 2024

Secondary Outcomes (3)

  • Sensitivity Analysis Using MR-Egger Intercept Test

    Oct 24 2024

  • Sensitivity Analysis Using Leave-One-Out Test

    Oct 24 2024

  • Sensitivity Analysis Using MR-PRESSO

    Oct 24 2024

Study Arms (2)

Allergic Rhinitis Cohort

This cohort consists of individuals with allergic rhinitis and a control group from the UK Biobank database, including 18,934 cases of allergic rhinitis and 64,595 controls. Genetic data were used to explore causal relationships with asthma.

Other: Mendelian Randomization

Asthma Cohort

This cohort includes individuals with asthma and a control group from the Finnish biobank database, consisting of 20,629 cases of asthma and 135,449 controls. Genetic data were analyzed to examine causal associations with allergic rhinitis.

Other: Mendelian Randomization

Interventions

This study utilizes a bidirectional Mendelian randomization approach to analyze genetic data from individuals with allergic rhinitis and asthma. No active intervention is applied; genetic variants serve as instrumental variables to assess causal associations between the conditions.

Allergic Rhinitis CohortAsthma Cohort

Eligibility Criteria

Age0 Years+
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

This study includes individuals diagnosed with allergic rhinitis or asthma from the UK Biobank and Finnish biobank databases.

You may qualify if:

  • Individuals diagnosed with allergic rhinitis or asthma.
  • Availability of genetic data in the UK Biobank or Finnish biobank.

You may not qualify if:

  • Individuals without genetic data.
  • Participants with incomplete phenotype or genotype data.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Guangzhou Institute of Respiratory Diseases, the First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, 510120, China

Location

MeSH Terms

Conditions

Rhinitis, AllergicAsthmaRespiratory Tract Diseases

Interventions

Mendelian Randomization Analysis

Condition Hierarchy (Ancestors)

RhinitisNose DiseasesRespiratory HypersensitivityOtorhinolaryngologic DiseasesHypersensitivity, ImmediateHypersensitivityImmune System DiseasesBronchial DiseasesLung Diseases, ObstructiveLung Diseases

Intervention Hierarchy (Ancestors)

Molecular EpidemiologyEpidemiologic MethodsInvestigative Techniques

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

October 30, 2024

First Posted

November 1, 2024

Study Start

October 1, 2024

Primary Completion

October 15, 2024

Study Completion

October 28, 2024

Last Updated

November 1, 2024

Record last verified: 2024-10

Locations